Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL

This study is testing a three-drug combination — zanubrutinib (a targeted pill), obinutuzumab (an antibody infusion), and sonrotoclax (a BCL-2 inhibitor) — as a first-line treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), two closely related slow-growing blood cancers. **You may be eligible if...** - You have a confirmed diagnosis of CLL or SLL - Your disease has reached a point where treatment is medically necessary - You have not received any prior systemic treatment for CLL or SLL (except short-course steroids or local radiation) **You may NOT be eligible if...** - You have already received systemic therapy for CLL or SLL (beyond steroids or local radiation) - You have significant heart, liver, or kidney problems - You have an active serious infection or autoimmune condition - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.